Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | MTTP | P55157 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5080882 | 0.74 | SMYD3 (0.50) | SMYD3NPY2RMTTP | |
| SCHEMBL6994952 | 0.69 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3SMYD3 | |
| SCHEMBL5838596 | 0.66 | ADRA2A (0.50) | — | |
| SCHEMBL5049558 | 0.63 | HTR1E (0.64) | SLC6A2SLC6A3 | |
| SCHEMBL14041885 | 0.63 | KMT2A (0.38) | — | |
| SCHEMBL19031918 | 0.63 | SLC6A1 (0.41) | — | |
| SCHEMBL12128460 | 0.62 | CPN1 (0.37) | SLC6A2SLC6A4SLC6A3SMYD3PLAT | |
| SCHEMBL5049482 | 0.62 | CYP1A2 (0.63) | SLC6A2SLC6A3 | |
| SCHEMBL5793357 | 0.62 | TSHR (0.59) | — | |
| SCHEMBL29013542 | 0.61 | SLC6A3 (0.58) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298009-A1 | Fused Pyrazole Derivatives As Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298009-A1 | Fused Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PI4K2B, PI4KB | CYP46A1 2038/4885AKT1 181/4885SLC6A2 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.